Indazole

Cat. No.: HY-40294 Purity: 99.83%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Indazole, also called isoindazole, a heterocyclic aromatic organic compound. Its derivatives display a broad variety of biological activities including anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour properties. Indazole and its derivatives can be used for research of cancer, neurological disorders, cardiovascular diseases, gastrointestinal diseases.

For research use only. We do not sell to patients.

Indazole Chemical Structure

CAS No. : 271-44-3

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	Get quote
50 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Indazole:

Indazole (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Monoamine Oxidase Isoform Specific Products:

View All Isoforms

MAO-A MAO-B

View All GSK-3 Isoform Specific Products:

View All Isoforms

GSK-3 GSK-3α GSK-3β

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Indazole compounds possess potential anticancer activity, and indazole-based agents such as, Axitinib.html" class="link-product" target="_blank">Axitinib (HY-10065) , Lonidamine.html" class="link-product" target="_blank">Lonidamine (HY-B0486) and Pazopanib.html" class="link-product" target="_blank">Pazopanib (HY-10208) have already been used for cancer research, demonstrating indazole compounds as useful templates for the development of novel anticancer agents^[1].
Indazoles show potent activities against neurological disorders by inhibiting the monoamine oxidase (MAO) and kinase enzymes like Glycogen synthase kinase 3 (GSK3), and leucinerich repeat kinase enzyme 2 (LRRK2)^[2].
Various natural and synthetic indazole derivatives Nigellicine, Nigellamine, Nigellidine, Zanubrutinib.html" class="link-product" target="_blank">Zanubrutinib (HY-101474A) and SCH772984.html" class="link-product" target="_blank">SCH772984 (HY-50846) showes prominent results to cure various gastrointestinal disorders^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

118.14

Formula

C₇H₆N₂

CAS No.

271-44-3

Appearance

Solid

Color

Light yellow to brown

SMILES

C12=CC=CC=C1NN=C2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (846.45 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	8.4645 mL	42.3227 mL	84.6453 mL
5 mM	1.6929 mL	8.4645 mL	16.9291 mL
10 mM	0.8465 mL	4.2323 mL	8.4645 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (42.32 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (42.32 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 5 mg/mL (42.32 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.83%

Select Batch:

Data Sheet (276 KB) SDS (393 KB)

COA (248 KB) HNMR (129 KB) RP-HPLC (216 KB) LCMS (329 KB)

Handling Instructions (2659 KB)

References

[1]. Shang C, et al. The Anticancer Activity of Indazole Compounds: A Mini Review. Curr Top Med Chem. 2021;21(5):363-376. [Content Brief]

[2]. Pal D, et al. Importance of Indazole against Neurological Disorders. Curr Top Med Chem. 2022;22(14):1136-1151. [Content Brief]

[3]. Uppulapu SK, et al. Indazole and its Derivatives in Cardiovascular Diseases: Overview, Current Scenario, and Future Perspectives. Curr Top Med Chem. 2022;22(14):1177-1188. [Content Brief]

[4]. Saha S, et al. Indazole Derivatives Effective against Gastrointestinal Diseases. Curr Top Med Chem. 2022;22(14):1189-1214. [Content Brief]

[5]. Qin J, et al. Indazole as a Privileged Scaffold: The Derivatives and their Therapeutic Applications. Anticancer Agents Med Chem. 2021;21(7):839-860. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	8.4645 mL	42.3227 mL	84.6453 mL	211.6133 mL
	5 mM	1.6929 mL	8.4645 mL	16.9291 mL	42.3227 mL
	10 mM	0.8465 mL	4.2323 mL	8.4645 mL	21.1613 mL
	15 mM	0.5643 mL	2.8215 mL	5.6430 mL	14.1076 mL
	20 mM	0.4232 mL	2.1161 mL	4.2323 mL	10.5807 mL
	25 mM	0.3386 mL	1.6929 mL	3.3858 mL	8.4645 mL
	30 mM	0.2822 mL	1.4108 mL	2.8215 mL	7.0538 mL
	40 mM	0.2116 mL	1.0581 mL	2.1161 mL	5.2903 mL
	50 mM	0.1693 mL	0.8465 mL	1.6929 mL	4.2323 mL
	60 mM	0.1411 mL	0.7054 mL	1.4108 mL	3.5269 mL
	80 mM	0.1058 mL	0.5290 mL	1.0581 mL	2.6452 mL
	100 mM	0.0846 mL	0.4232 mL	0.8465 mL	2.1161 mL

Indazole Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Indazole271-44-3Monoamine OxidaseGSK-3LRRK2MAOGlycogen synthase kinase-3Glycogen synthase kinase 3Leucine-rich repeat kinase 2cancerneurological disorderscardiovascular diseasesgastrointestinal diseasesisoindazoleParkinson's diseaseAlzheimer's diseaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *